Abstract
The major risk factor in diffuse pleural mesothelioma (PM) is occupational and/or geographical asbestos exposure. Surgery is a treatment option in only a limited number of cases. Prognosis is very poor with current therapies and new treatment options are needed. Immune checkpoint inhibitors (ICIs) may be a treatment option in PM, as in other malignant tumors. However, it is necessary to use predictive biomarkers to determine which patients will benefit from treatment. PD-L1 immunohistochemistry is widely used to predict therapy response to ICIs in many tumors.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
